Attached files
file | filename |
---|---|
EX-16.1 - EXHIBIT 16.1 - MABVAX THERAPEUTICS HOLDINGS, INC. | ex16-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 21,
2018
MABVAX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-37861
|
|
93-0987903
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer Identification
No.)
|
11535 Sorrento Valley Rd., Suite 400
San Diego, CA 92121
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code:
(858) 259-9405
N/A
(Former name or former address, if changed since last
report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company [ ]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. [ ]
EXPLANATORY NOTE
On May 21, 2018, MabVax Therapeutics Holdings, Inc. (the
“Company”) filed a Current Report on Form 8-K
(the “Original 8-K”) reporting matters relating
to, among other things, certain audit reports of the
Company’s independent auditors, CohnReznik LLP
(“CohnReznik”), included in its Forms 10-K and 10-Q for
the years 2014, 2015, 2016 and 2017. The Company provided
CohnReznick LLP with a copy of the disclosures made in the Original
8-K and requested that the auditors furnish the Company with a
letter addressed to the Securities and Exchange Commission stating
whether the auditors agree with the statements made by the Company
in the Original 8-K. This amended Current Report on Form 8-K/A is
being filed to include as Exhibit 16.1 a letter from
CohnReznick LLP. Other
than the inclusion of the letter from CohnReznik as Exhibit 16.1
filed herewith, there are no other changes to the Original
8-K.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) The following exhibit is furnished as part of this Amended
Current Report on Form 8-K:
|
|
|
|
Letter from
CohnReznick LLP to the Securities and
Exchange Commission, dated May 21, 2018.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
MABVAX THERAPEUTICS HOLDINGS, INC.
|
|
|
|
|
|||
Dated:
May 22, 2018
|
|
|
|
|
|
/s/ J. David
Hansen
|
|
|
|
|
|
|
J.
David Hansen
|
|
|
|
|
|
|
President and Chief Executive Officer
|